Orgenesis signs joint venture with Cure Therapeutics


The agreement aims to to advance point-of-care development and commercialisation of cell and gene therapies

Orgenesis and Cure Therapeutics have signed a joint venture agreement to advance the development, regulatory and governmental approval, and commercialisation of point of care production for both organisations’ cell and gene therapies and immunotherapies.

Under the agreement, the companies will collaborate in developing and commercialising Cure Therapeutics’ pipeline on a global basis, as well as developing, commercialising and supplying Orgenesis’ therapeutic pipeline in South Korea and Japan. Both companies will contribute at least $10m to cover operating costs, $5m of which may be provided in the form of in-kind contribution.

“This collaboration between Orgenesis and Cure Therapeutics further expands our cell and gene therapy pipeline and provides a clear illustration of the international scope of our POCare Platform,” said Vered Caplan, CEO of Orgenesis. “We selected Cure Therapeutics as our partner in South Korea and Japan given their expertise in the region, and robust immunotherapy pipeline. Additionally, this Agreement supports Orgenesis’ continued efforts to complement the Orgenesis pipeline and distribution efforts in the United States, Europe and globally.”

“The joint venture and partnership with Orgenesis will provide a significant international route to market for our immunotherapies targeting cancers and infectious diseases. Cure Therapeutics will leverage the Orgenesis POCare Network of leading international healthcare institutions to accelerate the international development and market approvals for our portfolio,” said David Kim, CEO of Cure Therapeutics. “In parallel, we will leverage our established network to help develop and rapidly advance the Orgenesis cell and gene therapy portfolio in South Korea and Japan.”

Sign up for your free email newsletter

The first focus of the partnership will be aligning the efforts of both companies to advance Orgenesis’s CAR-T, TILS and DUVAC therapies into clinical trials in South Korea and Japan. Process development and validation will be completed by leveraging the POCare Technologies from the Orgenesis platform to achieve automated manufacturing at the point of care.